Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 4.05M | $9.0M | 5.07% | +429.7K | 2026-06-30 |
| Renaissance Technologies LLC | 1.10M | $2.0M | 1.37% | -128.8K | 2026-06-30 |
| State Street Corp | 983.6K | $2.0M | 1.23% | +10.8K | 2026-06-30 |
| Geode Capital Management, LLC | 980.0K | $2.0M | 1.23% | +114.7K | 2026-06-30 |
| Northern Trust Corp | 922.3K | $2.0M | 1.15% | +36.9K | 2026-06-30 |
| Vanguard Portfolio Management LLC | 510.6K | $1.0M | 0.64% | +78.2K | 2026-06-30 |
| Stratos Wealth Partners, Ltd. | 500.0K | $1.0M | 0.63% | -- | 2026-06-30 |
| Dimensional Fund Advisors LP | 493.4K | $1.0M | 0.62% | +196.6K | 2026-06-30 |
| Goldman Sachs Group Inc | 475.9K | $1.0M | 0.60% | +224.6K | 2026-06-30 |
| Marshall Wace, LLP | 452.8K | $1.0M | 0.57% | +433.7K | 2026-06-30 |
